Mouse serum paraoxonase-1 lactonase activity is specific for medium-chain length fatty acid lactones

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1811, Issue 1, 2011, Pages 39-45

  Connelly, Philip W ^a   Picardo, Clive M ^a   Potter, Philip M ^b   Teiber, John F ^c   Maguire, Graham F ^a   Ng, Dominic S ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Lactones; Lactones; Carboxylesterase; ES 1; High density lipoprotein; Lactonase; Lactone; Mouse serum; Paraoxonase 1

Indexed keywords

3 OXO DODECANOYL HOMOSERINE LACTONE; 5 HYDROXY EICOSATETRAENOATE DELTA LACTONE; ARYLDIALKYLPHOSPHATASE 1; BENZYLSULFONYL FLUORIDE; CARBOXYLESTERASE; GAMMA LACTONE DERIVATIVE; GLUCONOLACTONASE; LACTONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; ENZYME ACTIVITY; ENZYME INHIBITION; HYDROLYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

ANIMALS; ARYLDIALKYLPHOSPHATASE; CARBOXYLESTERASE; ENZYME INHIBITORS; HYDROLYSIS; HYDROXYEICOSATETRAENOIC ACIDS; LACTONES; MICE; MICE, KNOCKOUT; PHENYLMETHYLSULFONYL FLUORIDE; SUBSTRATE SPECIFICITY;

MUS;

EID: 78649774614     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2010.10.002     Document Type: Article

References (29)

1. D.I. Draganov, and B.N. La Du Pharmacogenetics of paraoxonases: a brief review Naunyn-Schmiedebergs Arch. Pharmacol. 369 2004 78 88
2. O. Khersonsky, and D.S. Tawfik The histidine 115-histidine 134 dyad mediates the lactonase activity of mammalian serum paraoxonases J. Biol. Chem. 281 2006 7649 7656
3. Q. Liu, J.C. Docherty, J.C. Rendell, A.S. Clanachan, and G.D. Lopaschuk High levels of fatty acids delay the recovery of intracellular pH and cardiac efficiency in post-ischemic hearts by inhibiting glucose oxidation J. Am. Coll. Cardiol. 39 2002 718 725
4. C.D. Funk Lipoxygenase pathways as mediators of early inflammatory events in atherosclerosis Arterioscler. Thromb. Vasc. Biol. 26 2006 1204 1206
5. C.N. Serhan, and J. Savill Resolution of inflammation: the beginning programs the end Nat. Immunol. 6 2005 1191 1197
6. D.M. Shih, L. Gu, S. Hama, Y.R. Xia, M. Navab, A.M. Fogelman, and A.J. Lusis Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model J. Clin. Invest. 97 1996 1630 1639
7. C.L. Morton, M. Wierdl, L. Oliver, M.K. Ma, M.K. Danks, C.F. Stewart, J.L. Eiseman, and P.M. Potter Activation of CPT-11 in mice: identification and analysis of a highly effective plasma esterase Cancer Res. 60 2000 4206 4210
8. E.R. Soares Identification of a new allele of Es-I segregating in an inbred strain of mice Biochem. Genet. 17 1979 577 583
9. P.W. Connelly, G.F. Maguire, and D.I. Draganov Separation and quantitative recovery of mouse serum arylesterase and carboxylesterase activity J. Lipid Res. 45 2004 561 566
10. Y.C. Ha, and P.J. Barter Rapid separation of plasma lipoproteins by gel permeation chromatography on agarose gel Superose 6B J. Chromatogr. 341 1985 154 159
11. S.S. Kadner, J. Katz, M. Levitz, and T.H. Finlay The 65-kDa phorbol-diester hydrolase in mouse plasma is esterase 1 and is immunologically distinct from the 56-kDa phorbol-diester hydrolase in mouse liver J. Biol. Chem. 260 1985 15604 15609
12. D.I. Draganov, J.F. Teiber, A. Speelman, Y. Osawa, R. Sunahara, and B.N. La Du Human paraoxonases (PON1, PON2 and PON3) are lactonases with overlapping and distinct substrate specificities J. Lipid Res. 46 2005 1239 1247
13. J.F. Teiber, S. Horke, D.C. Haines, P.K. Chowdhary, J. Xiao, G.L. Krmaer, R.W. Haley, and D.I. Draganov Dominant role of paraoxonases in inactivation of the Pseudomonas aeruginosa quorum-sensing signal N-(3-oxododecanoyl)-l- homoserine lactone Infect. Immun. 76 2008 2512 2519
14. B. Li, M. Sedlacek, I. Manoharan, R. Boopathy, E.G. Duysen, P. Masson, and O. Lockridge Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma Biochem. Pharmacol. 70 2005 1673 1684
15. C.L. Morton, L. Iacono, J.L. Hyatt, K.R. Taylor, P.J. Cheshire, P.J. Houghton, M.K. Danks, C.F. Stewart, and P.M. Potter Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice Cancer Chemother. Pharmacol. 56 2005 629 636
16. T.R. Sharp, and T.L. Rosenberry A pseudo-first-order kinetic approach to measurement of acetylcholine hydrolysis by acetylcholineesterase J. Biochem. Biophys. Meth. 6 1982 159 172
17. J.F. Teiber, D.I. Draganov, and B.N. La Du Lactonase and lactonizing activities of human serum paraoxonase (PON1) and rabbit serum PON3 Biochem. Pharmacol. 66 2003 887 896
18. S.A. Goff, and H.J. Klee Plant volatile compounds: sensory cues for health and nutritional value? Science 311 2006 815 819
19. D.S. Lee, P. Nioche, M. Hamberg, and C.S. Raman Structural insights into the evolutionary paths of oxylipin biosynthetic enzymes Nature 455 2008 363 368
20. G.F. Zhang, R.S. Kombu, T. Kasumov, Y. Han, S. Sadhukhan, J. Zhang, L.M. Sayre, D. Ray, K.M. Gibson, V.A. Anderson, G.P. Tochtrop, and H. Brunengraber Catabolism of 4-hydroxyacids and 4-hydroxynonenal via 4-hydroxy-4-phosphoacyl- CoAs J. Biol. Chem. 284 2009 33521 33534
21. S. Sadhukhan, Y. Han, G.F. Zhang, H. Brunengraber, and G.P. Tochtrop Using isotopic tools to dissect and quantitate parallel metabolic pathways J. Am. Chem. Soc. 132 2010 6309 6311
22. D.S. Ng, T. Chu, B. Esposito, P. Hui, P.W. Connelly, and P.L. Gross Paraoxonase-1 deficiency in mice predisposes to vascular inflammation, oxidative stress, and thrombogenicity in the absence of hyperlipidemia Cardiovasc. Pathol. 2008
23. C.E. Furlong, T.B. Cole, G.P. Jarvik, C. Pettan-Brewer, G.K. Geiss, R.J. Richter, D.M. Shih, A.D. Tward, A.J. Lusis, and L.G. Costa Role of paraoxonase (PON1) status in pesticide sensitivity: genetic and temporal determinants Neurotoxicology 26 2005 651 659
24. T.B. Cole, B.J. Walter, D.M. Shih, A.D. Tward, A.J. Lusis, C. Timchalk, R.J. Richter, L.G. Costa, and C.E. Furlong Toxicity of chlorpyrifos and chlorpyrifos oxon in a transgenic mouse model of the human paraoxonase (PON1) Q192R polymorphism Pharmacogenet. Genomics 15 2005 589 598
25. W.F. Li, L.G. Costa, R.J. Richter, T. Hagen, D.M. Shih, A. Tward, A.J. Lusis, and C.E. Furlong Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds Pharmacogenetics 10 2000 767 779
26. L. Gaidukov, and D.S. Tawfik The development of human sera tests for HDL-bound serum PON1 and its lipolactonase activity J. Lipid Res. 48 2007 1637 1646
27. K. Ranade, T.G. Kirchgessner, O.A. Iakoubova, J.J. Devlin, T. DelMonte, P. Vishnupad, L. Hui, Z. Tsuchihashi, F.M. Sacks, M.S. Sabatine, E. Braunwald, T.J. White, P.M. Shaw, and N.C. Dracopoli Evaluation of the paraoxonases as candidate genes for stroke: Gln192Arg polymorphism in the paraoxonase 1 gene is associated with increased risk of stroke Stroke 36 2005 2346 2350
28. B. Mackness, P. Durrington, P. McElduff, J. Yarnell, N. Azam, M. Watt, and M. Mackness Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study Circulation 107 2003 2775 2779
29. T. Bhattacharyya, S.J. Nicholls, E.J. Topol, R. Zhang, X. Yang, D. Schmitt, X. Fu, M. Shao, D.M. Brennan, S.G. Ellis, M.L. Brennan, H. Allayee, A.J. Lusis, and S.L. Hazen Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk JAMA 299 2008 1265 1276